Back to results
US 2021/0231667 A1Published application
Method for detecting or monitoring prostate cancer
AssigneesOncosense Inc., Oncosense Inc. (USA)
InventorsHon Sing Leong, Colleen Nicole Biggs
Life of this patent
Estimating the term…
Abstract
The present invention provides methods identifying subjects having prostate cancer (PCa) by detecting in microparticles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having PCa from those having non-malignant prostate pathologies, including benign prostatic hyperplasia. Methods for monitoring prostate cancer and assessing efficacy of prostate cancer therapies are also disclosed. Kits for detecting prostate cancer using the methods disclosed are also provided.
Claims14
A kit for detecting prostate cancer in a bodily fluid sample, the kit comprising:
- a first binding probe specific to a first biomarker that is expressed by prostate epithelial cells, and
- a second binding probe specific to a second biomarker that is expressed by prostate cancer (PCa) cells but not by benign prostatic hyperplasia or other non-malignant prostate cells
- wherein:
- the first biomarker is prostate-specific membrane antigen (PSMA) and the first binding probe is anti-PSMA IgG, and,
- the second biomarker is Ghrelin and the second binding probe is Ghrelin-Cy5 or Ghrelin-FITC.
2 more elements
Dependencies are inferred from the claim text.